Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Anlotinib plus penpulimab: a new contender in first-line therapy for unresectable hepatocellular carcinoma.

Journal of gastrointestinal oncology·2026

Same author

A Study on the Association Between Treatment Response to Atezolizumab Plus Bevacizumab Combination Therapy for Advanced Hepatocellular Carcinoma and Gut Microbiota.

Microorganisms·2026

Same author

Durvalumab and tremelimumab combination therapy achieved remarkable response in primary hepatic undifferentiated carcinoma with high PD-L1 expression.

Clinical journal of gastroenterology·2026

Same author

Reply to "IL-6 as a biomarker in atezolizumab plus bevacizumab in patients with hepatocellular carcinoma".

Journal of gastroenterology·2026

Same author

A prioritization framework for BRCA1/2 variants of uncertain significance identified by comprehensive genomic profiling.

European journal of human genetics : EJHG·2026

Same author

Efficacy and Safety of Second-Line Lenvatinib After First-Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma.

Hepatology research : the official journal of the Japan Society of Hepatology·2026

Search research articles

Related Experiment Video

Updated: May 3, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Interleukin-28B polymorphisms and hepatitis C virus clearance.

Kazuaki Chayama¹, C Nelson Hayes¹

¹Department of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan ; Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN, Hiroshima 734-8551, Japan ; Liver Research Project Center, Hiroshima University, Hiroshima 734-8551, Japan.

Genome Medicine

|February 19, 2014

Summary

This summary is machine-generated.

Genetic variations in interleukin-28B (IL28B) strongly predict hepatitis C virus (HCV) treatment success. Recent meta-analyses refine these findings, supporting IL28B genotyping for personalized HCV therapy.

More Related Videos

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

Related Experiment Videos

Last Updated: May 3, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

Area of Science:

Genetics
Hepatology
Virology

Background:

Chronic hepatitis C virus (HCV) infection presents a significant global health challenge.
Treatment outcomes for HCV have historically varied widely among patients.
The discovery of genetic associations with treatment response marked a turning point in HCV management.

Purpose of the Study:

To summarize the current understanding of the association between genetic variation at the interleukin-28B (IL28B) locus and HCV infection outcomes.
To highlight the impact of recent meta-analyses on the precision of these genetic associations.
To underscore the clinical utility of IL28B genotyping in personalized medicine for HCV.

Main Methods:

Review of independent studies published since 2009 identifying associations between IL28B polymorphisms and HCV outcomes.
Analysis of a recent meta-analysis providing refined odds ratios for these genetic associations.
Synthesis of evidence regarding spontaneous HCV clearance and treatment response.

Main Results:

Consistent strong association between specific IL28B genetic variations and both spontaneous HCV clearance and treatment success.
Recent meta-analysis provides more precise estimates of the odds ratios for these associations.
IL28B genotyping emerged as a key predictive factor for treatment efficacy.

Conclusions:

Interleukin-28B (IL28B) genetic polymorphisms are critical determinants of hepatitis C virus (HCV) infection outcomes.
Precise genetic data supports the integration of IL28B genotyping into clinical practice.
This genetic information facilitates personalized treatment strategies for chronic HCV infection.